CAR-T cell therapy for relapsed B-cell ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or hasn't responded to standard treatments, and you can't wait for other options.
- You have leukemia cells in your bone marrow (detectable disease).
- You are in fairly good health overall (ECOG score 0-2) and your organs are working well enough.
- You have not had CAR-T therapy targeting CD19 before (except blinatumomab, which is a different type of drug).
- You do not have active leukemia in your brain or spinal cord, or certain other serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.